Core Insights - Precipio, Inc. will host its Q4 and year-end 2025 corporate update call on April 2, 2026, at 5:00 PM ET, providing updates on its core businesses [1] - Listeners can submit questions in advance via email, and a replay of the call will be available approximately 24 hours after the event [2] Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to reduce cancer misdiagnoses through innovative diagnostic products and services [3] - The company's products and services are designed to deliver higher accuracy, improve laboratory workflow, and enhance patient outcomes, ultimately reducing healthcare expenses [3] - Precipio develops and commercializes proprietary technologies that serve the global laboratory community, with a mission to eradicate misdiagnosis [3] Additional Information - For more information, stakeholders can visit Precipio's website or follow the company on social media platforms [4]

Core Viewpoint - Precipio, Inc. has introduced the Bloodhound BCR::ABL1 assay, the first assay capable of simultaneously detecting and quantifying all four clinically relevant BCR::ABL1 isoforms for Chronic Myeloid Leukemia (CML), setting a new standard for patient monitoring [1][2]. Group 1: Assay Features and Benefits - The Bloodhound BCR::ABL1 assay allows for comprehensive monitoring of disease progression by providing multiple data points from a single test, which is crucial as 25% of patients may have multiple BCR::ABL1 breakpoints that could be missed with traditional testing methods [3]. - This assay establishes a new standard for full quantification of BCR::ABL breakpoints, enabling clinicians to monitor treatment impact and detect early relapse with precise measurements [3][4]. - The assay demonstrates high sensitivity, capable of detecting changes as low as 1 in 100,000 cells (0.001%), which is essential for monitoring measurable residual disease (MRD) [4]. Group 2: Market Position and Innovation - Precipio's Bloodhound assay is the only clinical assay that can test multiple BCR::ABL1 isoforms simultaneously, eliminating the need for separate tests and enhancing laboratory workflow [5][6]. - The assay simplifies the testing process into one standardized test that can be run in various laboratory settings, including physician office laboratories and hospitals, thus improving accessibility [2][7]. - Precipio aims to address the issue of cancer misdiagnosis through innovative diagnostic products, ultimately improving patient outcomes and reducing healthcare costs [8].

Revenue Growth - Precipio's revenues grew to $24.0 million in 2025, a 30% increase year-over-year from $18.5 million in 2024[5] - Q4-2025 revenues were $6.7 million, representing a 23% year-over-year increase from $5.4 million in Q4-2024[5] Financial Performance - Adjusted EBITDA for Q4-2025 was reported at $0.95 million, compared to $0.40 million in Q4-2024, while the full year 2025 Adjusted EBITDA was $1.23 million, up from a loss of $1.5 million in 2024[5] - Positive operating cash flow of $368,000 was generated in Q4-2025, totaling $688,000 for the full year 2025, compared to $439,000 in 2024[5] - Adjusted operating cash flow, excluding unusual items, was $617,000 for Q4-2025 and $727,000 for the full year 2025[5] - The company emphasizes the importance of Adjusted EBITDA as a measure of financial health, particularly for emerging growth companies[4] Strategic Focus - The company aims to invest in growth projects now that it has achieved EBITDA and cash-flow positivity, allowing for a longer-term perspective[3] - Precipio is focused on developing innovative cancer diagnostic technologies to improve accuracy and patient outcomes, which is expected to reduce healthcare expenses[7] Shareholder Value - Shareholders saw their value triple in 2025, indicating strong performance and confidence in future growth[3] - The company plans to provide more detailed information on its performance and prospects for 2026 in an upcoming shareholder call[3]

Core Insights - Precipio, Inc. has reported strong preliminary financial results for Q4-2025 and fiscal year 2025, highlighting significant growth in revenue and positive cash flow metrics [1][5]. Financial Performance - Revenue Growth: Precipio's revenues increased from $18.5 million in 2024 to $24.0 million in 2025, representing a 30% year-over-year increase. Q4-2025 revenues were $6.7 million, up 23% from $5.4 million in Q4-2024 [5]. - Positive Adjusted EBITDA: The company will report Adjusted EBITDA of $0.95 million for Q4-2025 and $1.23 million for the full year 2025, compared to $0.40 million in Q4-2024 and a loss of $1.5 million for the full year 2024 [5]. - Positive Operating Cash Flow: Precipio will report $368,000 of positive operating cash flow during Q4-2025 and a total of $688,000 for 2025, compared to $439,000 generated from operations in 2024 [5]. Management Commentary - The CEO, Ilan Danieli, emphasized the importance of becoming an EBITDA and cash-flow positive business, allowing for investments in long-term growth projects rather than focusing solely on short-term cash burn [2]. The company experienced a strong performance in 2025, with shareholders seeing their value triple [2]. Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services that enhance accuracy and improve patient outcomes [6].

Core Insights - Precipio, Inc. has significantly improved its balance sheet by repaying a $1.1 million advance from Change Healthcare and exercising all financial warrants, resulting in a debt-free status aside from a minor loan of approximately $80,000 [1][3][2] Financial Improvements - The company repaid a $1.1 million advance from Change Healthcare, which was initially provided to cover collections shortfalls due to a cybersecurity incident in 2024 [1] - Precipio maintains a small loan with the Connecticut Department of Economic and Community Development, with a principal amount of approximately $80,000, amortized at $3,000 per month and a 3.25% interest rate, to be fully paid by May 2028 [2] - All financial warrants issued during a 2023 financing have been exercised, with no further financial warrants outstanding [3] Operational Focus - The company emphasizes its commitment to profitable operations and a clean balance sheet, which reduces financial risk for shareholders [4] - Management is focused on executing its business strategy to grow the business, increase profit margins, and create sustained shareholder value [4] Company Overview - Precipio is a healthcare biotechnology company specializing in cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services [5] - The company's products and services are designed to deliver higher accuracy and improved laboratory workflow, ultimately enhancing patient outcomes and reducing healthcare expenses [5]

Core Insights - The Zacks Equity Research team has highlighted several stocks, including AbbVie Inc., The Coca-Cola Co., Chevron Corp., ImmuCell Corp., and Precipio, Inc., in their Analyst Blog [1][2]. AbbVie Inc. (ABBV) - AbbVie has outperformed the Zacks Large Cap Pharmaceuticals industry over the past year, with a share price increase of +31.6% compared to the industry’s +19.5% [4]. - The company has successfully managed the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are performing well and expected to support revenue growth [4][5]. - AbbVie is returning to robust revenue growth in 2025, following the U.S. Humira loss of exclusivity, and has been actively acquiring companies to enhance its early-stage pipeline [5]. The Coca-Cola Co. (KO) - Coca-Cola's shares have outperformed the Zacks Beverages - Soft Drinks industry over the past year, with a gain of +14.5% compared to +10.5% for the industry [6]. - The company's performance is attributed to solid organic revenue growth, effective pricing strategies, and gains in global market share within the non-alcoholic ready-to-drink category [6][7]. - Ongoing innovation and digital transformation efforts are enhancing Coca-Cola's competitive edge, although the company faces challenges such as soft volumes in key regions and currency headwinds [7][8]. Chevron Corp. (CVX) - Chevron's shares have increased by +9.5% over the past year, while the Zacks Oil and Gas - Integrated - International industry has gained +16% [9]. - The acquisition of Hess has significantly improved Chevron's growth outlook by adding high-quality assets in regions like Guyana and the Gulf of Mexico [9]. - The Permian Basin remains a key asset for Chevron, driving consistent growth, although challenges such as lower crude realizations and regulatory issues in California temper optimism [10]. ImmuCell Corp. (ICCC) - ImmuCell has outperformed the Zacks Medical - Products industry with a share price increase of +26.3% compared to +1% for the industry [11]. - The company’s First Defense franchise leads the market in calf scours prevention, with Tri-Shield accounting for 70% of volume and a 48% market share [11][12]. - ImmuCell has resolved operational bottlenecks, restoring capacity to $30 million in annual sales, with TTM revenues of $27.8 million, reflecting a 16% year-over-year increase [12][13]. Precipio, Inc. (PRPO) - Precipio's shares have surged by +361.2% over the past year, significantly outperforming the Zacks Medical Info Systems industry, which saw a decline of -1.3% [14]. - The company is moving towards self-funded growth, driven by its Pathology Services division, which is experiencing steady organic growth and rising margins [14][15]. - Precipio has improved profitability and cash flow, although it faces risks related to liquidity and regulatory uncertainties [15][16].

Core Insights - Precipio, Inc. is set to present findings from a joint study with Memorial Sloan Kettering Cancer Center, highlighting the positive impacts of its BCR::ABL1 assay on patient care [1][2] Group 1: Study Findings - The comprehensive study involved 895 patient samples and demonstrated superior performance of the BCR::ABL1 assay, showing concordance with two other leading platforms [2] - The study indicates clear, positive impacts on patient care and significant improvements in laboratory workflows [2] Group 2: Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services [3] - The company's mission includes delivering higher accuracy and improved laboratory workflow, ultimately leading to better patient outcomes and reduced healthcare expenses [3]

Core Viewpoint - Precipio, Inc. reported a limited unauthorized access incident to a specific data folder within its secure cloud environment, which did not affect its operations, diagnostics, or customer services [1][5]. Incident Details - The unauthorized access was confined to a file storage server and did not impact patient care or the company's financials [1][5]. - An external cybersecurity law firm and forensic specialists were engaged to assist in the investigation and ensure system security [2]. - The investigation revealed that the unauthorized party accessed historical files containing operational procedures, temperature logs, and vendor invoices, which posed no risk to the company [3]. Security Measures - The company took immediate action to secure its environment, including resetting passwords company-wide and enhancing monitoring [2][4]. - Current assessments suggest that the incident was limited in scope, and systems remain stable [4]. Financial Implications - Precipio maintains a comprehensive cybersecurity insurance policy, which is expected to cover costs related to the investigation and response efforts [5]. - The company does not anticipate any material impact on its operations, customers, patient care, or shareholders as a result of this incident [5]. Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to reduce cancer misdiagnoses through innovative diagnostic products and services [6]. - The company develops technologies to improve diagnostic outcomes and commercializes these as proprietary products for the global laboratory community [6].

Core Viewpoint - Precipio, Inc. (PRPO) has demonstrated significant financial improvement in Q3 2025, with strong revenue growth and operational momentum, leading to a notable increase in stock performance compared to the broader market [1][2]. Financial Performance - Revenue for Q3 2025 increased by 29.9% year over year to $6.8 million from $5.2 million, and sequentially rose by 19.7% from $5.7 million in Q2 2025 [2]. - Adjusted EBITDA improved to $0.5 million from $0.1 million a year ago and from a loss of $0.1 million in the prior quarter [2][4]. - Gross margin increased to 44% from 43% in Q2 2025, while GAAP net loss narrowed to $0.1 million from $0.6 million in Q3 2024 [2]. Segment Performance - The Pathology Services division saw a 20% sequential revenue increase to $6 million, driven by new customer additions [3]. - The Products division experienced a 16% sequential revenue growth to $0.7 million, supported by increased orders from existing clients [3]. Operational Metrics - EBITDA reached $0.3 million in Q3 2025, compared to a loss of $0.3 million in the same quarter last year [4]. - Operating cash flow generated was $285,000, a significant improvement from a cash burn of $148,000 in Q2 2025 [4]. Margin Dynamics - Pathology Services gross margin improved from 43% to 46% quarter over quarter, while the Products division margin fell from 44% to 30% due to strategic investments [5][11]. - Management expects that revenue scaling will offset temporary margin pressures from these investments [5]. Management Insights - Management characterized the quarter as a turning point, emphasizing a shift from survival to strategic expansion, with a focus on operational discipline and sustained revenue gains [6]. - The company aims to operate without dependence on external capital, allowing for reinvestment in growth initiatives [6]. Future Outlook - Management outlined four priorities for the remainder of 2025 and into 2026: sustaining double-digit growth, further margin expansion, reinvestment of internally generated cash, and broader investor outreach [12]. - PRPO expects overall company gross margins to exceed 50% by mid-2026 as revenue scales against a largely fixed-cost structure [12]. Other Developments - The company expanded its laboratory space during Q3 2025, incurring an additional $120,000 in annual rent, aimed at increasing operational efficiency [14].

Core Viewpoint - The conference call is focused on providing a shareholder update for Precipio's third quarter of 2025, highlighting forward-looking statements about the company's business performance and expectations [1][3]. Group 1: Forward-Looking Statements - The statements made during the call include forward-looking statements that are based on current expectations, forecasts, and assumptions, which are subject to significant risks and uncertainties [1]. - Forward-looking statements may include terms such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, and continue [1]. Group 2: Risks and Uncertainties - Actual results may differ materially from those set forth in forward-looking statements due to various risks and uncertainties [2]. - The company references its annual report on Form 10-K for the year ended December 31, 2024, which details risk factors that could impact results [2].